Literature DB >> 3298185

Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent.

S P Gorman, D F McCafferty, A D Woolfson, D S Jones.   

Abstract

Taurolin, a non-antibiotic antimicrobial agent, significantly reduced the adherence of buccal and vaginal strains of Candida albicans blastospores and urine isolates of Escherichia coli and Staphylococcus saprophyticus to epithelial cells. Light microscopy and radio-isotopic counting methods were used to quantify the adherence of the micro-organisms to either uroepithelial or buccal epithelial cells. A maximum reduction in adherence of approximately 65% was obtained. The anti-adherence capacity was time-dependent, requiring a contact time of 30 min to achieve maximum effect. Taurolin at sub-minimum inhibitory concentrations (MIC) significantly reduced the adherence of Candida and E. coli. A concentration slightly higher than the MIC was required for Staph. saprophyticus. Treatment of either epithelial cells or micro-organisms with Taurolin resulted in reduced adherence of microorganisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298185     DOI: 10.1111/j.1365-2672.1987.tb04926.x

Source DB:  PubMed          Journal:  J Appl Bacteriol        ISSN: 0021-8847


  18 in total

1.  Effect of peritoneal lavage with taurolidine on primary colonic anastomosis in a rat model of secondary peritonitis.

Authors:  Aşkin Akkuş; Mustafa Gülmen; Ayhan Cevik; Nejdet Bildik; Orhan Sad; Erdem Oztürk; Nagihan Ozdemir Barişik
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

2.  Comparative in vitro efficacies of various catheter lock solutions.

Authors:  Robert J Sherertz; Michael S Boger; Casey A Collins; Lori Mason; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats.

Authors:  C Braumann; J Ordemann; P Wildbrett; C A Jacobi
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Efficacy of taurolidine against periodontopathic species--an in vitro study.

Authors:  Sigrun Eick; Sabrina Radakovic; Wolfgang Pfister; Sandor Nietzsche; Anton Sculean
Journal:  Clin Oral Investig       Date:  2011-05-24       Impact factor: 3.573

5.  The effects of hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis.

Authors:  D S Jones; J G McGovern; A D Woolfson; S P Gorman
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

6.  Taurolidine antiadhesive properties on interaction with E. coli; its transformation in biological environment and interaction with bacteria cell wall.

Authors:  Francesco Caruso; James W Darnowski; Cristian Opazo; Alexander Goldberg; Nina Kishore; Elin S Agoston; Miriam Rossi
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

7.  Taurine modulates neutrophil function but potentiates uropathogenic E. coli infection in the murine bladder.

Authors:  Claire Condron; Rowan G Casey; Siobhan Kehoe; Deirdre Toomey; Tom Creagh; David J Bouchier-Hayes
Journal:  Urol Res       Date:  2009-11-26

8.  Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines.

Authors:  Denise K Walters; Roman Muff; Bettina Langsam; Philipp Gruber; Walter Born; Bruno Fuchs
Journal:  Invest New Drugs       Date:  2007-04-26       Impact factor: 3.850

9.  Influence of selective decontamination of the digestive tract on microbial biofilm formation on endotracheal tubes from artificially ventilated patients.

Authors:  S Gorman; C Adair; F O'Neill; C Goldsmith; H Webb
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

10.  Adherence of Candida albicans to tissues from mice with genetic immunodeficiencies.

Authors:  D L Brawner; F O Smith; M Mori; S Nonoyama
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.